A Clinical Study to Investigate the Safety and Immunogenicity of rVSV∆G-SUDV-GP, a Sudan Virus (SUDV) Vaccine for the Prevention of SUDV Disease in Adults in Good General Health
Part of paid clinical trials in Washington D.C., District of Columbia.
- Sponsor
- International AIDS Vaccine Initiative
- Study ID
- NCT07565090
- Phase
- PHASE1
- Status
- Not Yet Recruiting
Notify me when recruiting opens
Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.
Add your contact details and location so we can keep your interest tied to this study.
Conditions
- Sudan Virus Disease
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 50 Years
- Healthy Volunteers
- Accepted
Interventions
- rVSVΔG-SUDV-GP — BIOLOGICALrVSVΔG-SUDV-GP
- Placebo — OTHERPlacebo
Study Details
A Clinical Study to Investigate the Safety and Immunogenicity of rVSV∆G-SUDV-GP, a Sudan Virus (SUDV) Vaccine for the Prevention of SUDV Disease in Adults in Good General Health.
Key Dates
- Start date
- May 31, 2026
- Status verified
- May 2026
- Primary completion
- Apr 30, 2027
- Completion
- Apr 30, 2027
Study Design
- Enrollment
- 112 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- SINGLE_GROUP
- Primary purpose
- PREVENTION
Arms
- Experimental: rVSVΔG-SUDV-GPrVSVΔG-SUDV-GP
- Placebo Comparator: PlaceboPlacebo/Diluent
Primary Outcome Measure
Safety and tolerability of rVSVΔG-SUDV-GP vaccination: solicited reactogenicity [ Time Frame: 14 Days ]
Central Contacts
- Johannes Beeslaar, MD212-328-7459
Locations (3)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| George Washington University | Washington D.C. | District of Columbia | 20037 | Aimee Desrosiers David Diemert, MD (PRINCIPAL_INVESTIGATOR) |
| Johnson County Clin-Trials | Lenexa | Kansas | 66219 | |
| Brigham and Women's Hospital | Boston | Massachusetts | 02115 | Lindsey Baden, MD (PRINCIPAL_INVESTIGATOR) |